Latest news
Nintedanib dry powder inhalation therapy has favorable safety, tolerability in IPF - HealioHealio · Fri, 07 Aug 2026 20:09:31 GMTMannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway - TradingViewTradingView · Wed, 29 Jul 2026 23:04:07 GMTMannKind Reports Positive Topline Results from Phase 1b INFLO-1 Study of Nintedanib Dry Powder Inhalation in Idiopathic Pulmonary Fibrosis - Quiver QuantitativeQuiver Quantitative · Wed, 29 Jul 2026 10:42:00 GMT